Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods

UMMS Affiliation

Department of Psychiatry

Publication Date


Document Type



Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Molindone; Risperidone; Schizophrenia; Time Factors




OBJECTIVE: The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described.

METHOD: Using a randomized, double-blind, parallel-group design at four sites, youths with EOSS (ages 8-19 years) were assigned to an 8-week acute trial of risperidone (0.5-6.0 mg/day), olanzapine (2.5-20 mg/day), or molindone (10-140 mg/day). Responders continued double-blind treatment for 44 weeks. The primary outcome measure was responder status at 8 weeks, defined by a 20% reduction in baseline Positive and Negative Symptom Scale scores plus ratings of significant improvement on the Clinical Global Impressions. Secondary outcome measures included assessments of psychopathology, functional impairment, quality of life, and medication safety. An intent-to-treat analytic plan was used.

RESULTS: From February 2002 to May 2006, 476 youths were screened, 173 were further evaluated, and 119 were randomized. Several significant study modifications were required to address safety, the use of adjunctive medications, and the termination of the olanzapine treatment arm due to weight gain.

CONCLUSIONS: The Treatment of Early Onset Schizophrenia Spectrum Disorders Study will inform clinical practice regarding the use of antipsychotic medications for youths with early-onset schizophrenia spectrum disorders. Important safety concerns emerged during the study, including higher than anticipated rates of suicidality and problems tapering thymoleptic agents before randomization.

DOI of Published Version



J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):969-78. Link to article on publisher's site

Journal/Book/Conference Title

Journal of the American Academy of Child and Adolescent Psychiatry

Related Resources

Link to Article in PubMed

PubMed ID